Urinary pS2/TFF1 levels in the management of hormonodependent breast carcinomas.
pS2/TFF1 overexpression in breast carcinomas correlates with response to hormonotherapy. We evaluated the clinical relevance of urinary pS2/TFF1 in breast cancer patients. In healthy controls (100 cases), it represents an individual and relatively stable parameter. Although 24 out 83 pre-operative breast cancer patients showed elevated levels, both the sensitivity and specificity of the test were too low for breast cancer screening. However, neoadjuvant hormonotherapy decreased pS2/TFF1 levels in nine out of 20 patients. Furthermore, among 22 patients receiving long-term adjuvant hormonotherapy, four exhibited elevated levels, two of them at the time of relapse. Thus, urinary pS2/TFF1 quantification might be suitable as an in vivo diagnosis for tumor hormonodependency, and disease follow-up during hormonotherapy.
Chenard
Marie-Pierre
MP
Service d'Anatomie Pathologique Générale, Centre Hospitalier Universitaire de Hautepierre, 67098 Strasbourg Cedex, France.
Tomasetto
Catherine
C
Bellocq
Jean-Pierre
JP
Rio
Marie-Christine
MC
D001943:Breast Neoplasms / Q000188:drug therapy / Q000378:metabolism*; D004965:Estrogen Antagonists / Q000494:pharmacology; D020249:Hormone Replacement Therapy; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy / Q000378:metabolism*; D011506:Proteins / Q000032:analysis*; D013629:Tamoxifen / Q000494:pharmacology; D000071163:Trefoil Factor-1; D025521:Tumor Suppressor Proteins; D014556:Urine / Q000737:chemistry*
D004965:Estrogen Antagonists; D011506:Proteins; C051838:TFF1 protein, human; D000071163:Trefoil Factor-1; D025521:Tumor Suppressor Proteins; D013629:Tamoxifen